Endocrine Community Makes Progress in Advancing EU EDC Regulations

In recent weeks, organizations around the world have intensified their lobbying efforts for better regulation of endocrine-disrupting chemicals (EDCs) and the Endocrine Society’s members continue to play a leading role as the voice of science in high-level discussions.

In the European Union, the Commission is under a tight deadline to deliver reforms to the regulation on Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH), which governs restrictions on EDCs. To ensure prioritization of this reform we partnered with the European Society of Endocrinology (ESE) to organize a petition to Commission President Ursula von der Leyen emphasizing the urgent need to deliver a legislative proposal to revise REACH by June 2023. The petition was co-signed by 44 European and international endocrine-focused scientific societies and delivered to members of the European Parliament and other policymakers with an interest in EDCs. The petition generated significant attention and was reported on by Politico EU noting our “United Front.”

Organizations around the world have intensified their lobbying efforts for better regulation of endocrine-disrupting chemicals and the Endocrine Society’s members continue to play a leading role as the voice of science in high-level discussions.

Additionally, we signed a letter organized by the European Environment Bureau and supported by 11 other members of a high-level strategic advisory group on chemicals and sustainability to urge the European Commissioner for the Internal Market, Thierry Breton, to support a prompt revision of REACH to ensure harmonized and predictable regulatory approaches to chemicals, including EDCs, across the EU. Reforms to the REACH regulation are necessary to ensure that new regulatory classes that identify hazardous EDCs can be implemented to reduce exposure to these harmful chemicals.

You may also like

  • Endocrine Society Advocacy Updates

    Endocrine Society Endorses Right to IVF Act  In June 2024, the Endocrine Society endorsed the Right to IVF Act, introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA), and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF). The Right to IVF Act would help individuals and families…

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…